ID

37427

Descrição

Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH); ODM derived from: https://clinicaltrials.gov/show/NCT02290613

Link

https://clinicaltrials.gov/show/NCT02290613

Palavras-chave

Versões (1)
  1. 25/07/2019 25/07/2019 -
Titular dos direitos

See clinicaltrials.gov

Transferido a

25 de julho de 2019

DOI

Para um pedido faça login.

Licença

Creative Commons BY 4.0
Comentários do modelo :

Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.

Voltar para os comentários do modelo
Comentários do grupo de itens para :

Comentários do item para :

Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.

Eligibility Systemic Sclerosis NCT02290613

Inglês

Eligibility Systemic Sclerosis NCT02290613

1 Formulários  
Inclusion Criteria
Descrição

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. mpap 21-24 mmhg, tpg > 11mmhg, pawp <15 mmhg and/or
Descrição

Mean pulmonary arterial pressure | Pulmonary artery pressure Gradient | Pulmonary Wedge Pressure

Tipo de dados

boolean

Alias
UMLS CUI [1]
C3854605
UMLS CUI [2,1]
C0428642
UMLS CUI [2,2]
C0812409
UMLS CUI [3]
C0034094
2. exercise induced elevated mpap-values >30 mmhg, pawp <18 mmhg; tpg >15 mmhg, as defined in saggar et al. (2012) without left heart or severe lung disease or systemic arterial hypertension
Descrição

Mean pulmonary arterial pressure increased Exercise induced | Pulmonary Wedge Pressure Exercise induced | Pulmonary artery pressure Gradient Exercise induced | Heart Disease Left sided Absent | Lung disease Severe Absent | Hypertensive disease Absent

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C4087413
UMLS CUI [1,2]
C0239313
UMLS CUI [2,1]
C0034094
UMLS CUI [2,2]
C0239313
UMLS CUI [3,1]
C0428642
UMLS CUI [3,2]
C0812409
UMLS CUI [3,3]
C0239313
UMLS CUI [4,1]
C0018799
UMLS CUI [4,2]
C0443246
UMLS CUI [4,3]
C0332197
UMLS CUI [5,1]
C0024115
UMLS CUI [5,2]
C0205082
UMLS CUI [5,3]
C0332197
UMLS CUI [6,1]
C0020538
UMLS CUI [6,2]
C0332197
3. adult patients having completed his/her 18th birthday
Descrição

Adult | Age

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0001675
UMLS CUI [2]
C0001779
4. patients with definite diagnosis of systemic sclerosis using the scleroderma criteria of the american rheumatism association
Descrição

Systemic Sclerosis

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0036421
5. ssc-disease duration >3 years
Descrição

Systemic Sclerosis Disease length

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0036421
UMLS CUI [1,2]
C0872146
6. able to understand and willing to sign the informed consent form
Descrição

Informed Consent

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0021430
7. negative pregnancy test at the start of the trial and appropriate contraception throughout the study for women with child-bearing potential.
Descrição

Childbearing Potential Pregnancy test negative | Childbearing Potential Contraceptive methods

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C3831118
UMLS CUI [1,2]
C0427780
UMLS CUI [2,1]
C3831118
UMLS CUI [2,2]
C0700589
Exclusion Criteria
Descrição

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. any connective tissue diseases (ctd) other than ssc
Descrição

Connective Tissue Diseases | Exception Systemic Sclerosis

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0009782
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0036421
2. pulmonary hypertension (ph) confirmed by right heart catheter (rhc) before enrolment, i.e. mpap ≥25 mmhg at rest
Descrição

Pulmonary Hypertension Catheterization of right heart | Mean pulmonary arterial pressure At rest

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0020542
UMLS CUI [1,2]
C0189896
UMLS CUI [2,1]
C3854605
UMLS CUI [2,2]
C0443144
3. patients presenting normal mpap values, i.e. mpap<21 mmhg at rest, ≤30 mmhg during exercise, pawp >=15 mmhg at rest or <=18 mmhg during exercise
Descrição

Mean pulmonary arterial pressure Normal | Mean pulmonary arterial pressure At rest | Mean pulmonary arterial pressure Exercise induced | Pulmonary Wedge Pressure At rest | Pulmonary Wedge Pressure Exercise induced

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C3854605
UMLS CUI [1,2]
C0205307
UMLS CUI [2,1]
C3854605
UMLS CUI [2,2]
C0443144
UMLS CUI [3,1]
C3854605
UMLS CUI [3,2]
C0239313
UMLS CUI [4,1]
C0034094
UMLS CUI [4,2]
C0443144
UMLS CUI [5,1]
C0034094
UMLS CUI [5,2]
C0239313
4. ongoing or a history of >2 weeks of continued use of therapies that are considered definitive ph treatment: endothelin receptor antagonists (era; e.g. bosentan, ambrisentan), phosphodiesterase type 5 inhibitors (pde5; e.g. sildenafil, tadalafil, vardenafil), prostanoids (e.g. epoprostenol, treprostinil, iloprost, beraprost) and soluble guanylate cyclase stimulator (e.g. riociguat). intermittent use of pde5 inhibitors for male erectile dysfunction is permitted.
Descrição

Therapy Pulmonary Hypertension | Endothelin receptor antagonist | bosentan | ambrisentan | Phosphodiesterase 5 inhibitor | sildenafil | tadalafil | vardenafil | Prostaglandins | Epoprostenol | Treprostinil | Iloprost | beraprost | Soluble Guanylate Cyclase Stimulator | riociguat

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C0020542
UMLS CUI [2]
C1134681
UMLS CUI [3]
C0252643
UMLS CUI [4]
C1176329
UMLS CUI [5]
C1318700
UMLS CUI [6]
C0529793
UMLS CUI [7]
C1176316
UMLS CUI [8]
C0971579
UMLS CUI [9]
C0033554
UMLS CUI [10]
C0033567
UMLS CUI [11]
C1145760
UMLS CUI [12]
C0079594
UMLS CUI [13]
C0053336
UMLS CUI [14]
C3819023
UMLS CUI [15]
C2717561
5. except for diuretics and corticosteroids medical treatment should not be expected to change 4 weeks prior inclusion into the study and during the entire 12-week study period.
Descrição

Exception Diuretics | Exception Adrenal Cortex Hormones | Therapeutic procedure unchanged

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C1705847
UMLS CUI [1,2]
C0012798
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0001617
UMLS CUI [3,1]
C0087111
UMLS CUI [3,2]
C0442739
6. known intolerance to ambrisentan or one of its excipients
Descrição

Intolerance to Ambrisentan | Intolerance to Ambrisentan Excipient

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C1744706
UMLS CUI [1,2]
C1176329
UMLS CUI [2,1]
C1744706
UMLS CUI [2,2]
C1176329
UMLS CUI [2,3]
C0015237
7. clinically significant anemia (hemoglobin concentration of less than 75% of the lower limit of normal, lln)
Descrição

Anemia | Hemoglobin measurement

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0002871
UMLS CUI [2]
C0518015
8. forced vital capacity (fvc) <60%, forced expiratory volume in first second (fev1) <65%
Descrição

FVC | FEV1

Tipo de dados

boolean

Alias
UMLS CUI [1]
C3714541
UMLS CUI [2]
C0849974
9. severe interstitial lung disease, idiopathic pulmonary fibrosis
Descrição

Interstitial Lung Disease Severe | Idiopathic Pulmonary Fibrosis

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0206062
UMLS CUI [1,2]
C0205082
UMLS CUI [2]
C1800706
10. renal insufficiency (glomerular filtration rate [gfr] <60 ml/min/1.73m2 for at least 3 months)
Descrição

Renal Insufficiency | Glomerular Filtration Rate

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1565489
UMLS CUI [2]
C0017654
11. baseline values of hepatic aminotransferases (alt and/or ast) >3 x upper limit of normal (uln)
Descrição

Alanine aminotransferase increased | Aspartate aminotransferase increased

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0151905
UMLS CUI [2]
C0151904
12. systolic blood pressure <85 mmhg;
Descrição

Systolic Pressure

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0871470
13. evidence of inadequately treated blood pressure >160/90 mmhg and/or blood pressure during exercise >220/120 mmhg
Descrição

Blood pressure determination | Therapy Inadequate | Blood pressure determination During Exercise

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0005824
UMLS CUI [2,1]
C0087111
UMLS CUI [2,2]
C0205412
UMLS CUI [3,1]
C0005824
UMLS CUI [3,2]
C0347984
UMLS CUI [3,3]
C0015259
14. patients referred with clinically significant overt heart failure
Descrição

Heart failure

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0018801
15. clinically significant fluid retention
Descrição

Body fluid retention

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0268000
16. previous evidence or diagnosis of clinically relevant left heart disease, i.e. at least one of the following: previous echocardiography with estimated left ventricular (lv) ejection fraction <50%, previous history of cardiogenic pulmonary edema, increased size of left atrium (>50 mm)
Descrição

Heart Disease Left sided | Estimated Left Ventricular Ejection Fraction Echocardiography | Cardiogenic pulmonary edema | Left atrium Size Increased

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0018799
UMLS CUI [1,2]
C0443246
UMLS CUI [2,1]
C4525751
UMLS CUI [2,2]
C0013516
UMLS CUI [3]
C0398350
UMLS CUI [4,1]
C0225860
UMLS CUI [4,2]
C0456389
UMLS CUI [4,3]
C0205217
17. known significant diastolic dysfunction associated with clinical heart failure
Descrição

Diastolic dysfunction Associated with Heart failure

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0520863
UMLS CUI [1,2]
C0332281
UMLS CUI [1,3]
C0018801
18. known coronary disease or significant valvular heart disease
Descrição

Coronary Artery Disease | Heart valve disease

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1956346
UMLS CUI [2]
C0018824
19. known congenital heart defects such as single ventricle, transposition, eisenmenger
Descrição

Congenital Heart Defects | Single Ventricle | Transposition | Eisenmenger Complex

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0018798
UMLS CUI [2]
C3274516
UMLS CUI [3]
C0040759
UMLS CUI [4]
C0013743
20. known hypertrophic cardiomyopathy or left ventricular hypertrophy (interventricular septum thickness (ivs) or posterior wall thickness (pwd) >1.2 cm)
Descrição

Hypertrophic Cardiomyopathy | Left Ventricular Hypertrophy | Interventricular septum thickness increased | Posterior wall thickness increased

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0007194
UMLS CUI [2]
C0149721
UMLS CUI [3]
C3553443
UMLS CUI [4]
C3553444
21. participation in any clinical drug trial within 4 weeks prior to screening of this study and/or who is scheduled to receive another investigational medicinal product (imp) during the course of this study
Descrição

Study Subject Participation Status | Investigational New Drugs

Tipo de dados

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C0013230
22. pregnancy or lactation
Descrição

Pregnancy | Breast Feeding

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
Voltar ao início da página

Similar models

Eligibility Systemic Sclerosis NCT02290613

1 Formulários
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
C1512693 (UMLS CUI)
Mean pulmonary arterial pressure | Pulmonary artery pressure Gradient | Pulmonary Wedge Pressure
Item
1. mpap 21-24 mmhg, tpg > 11mmhg, pawp <15 mmhg and/or
boolean
C3854605 (UMLS CUI [1])
C0428642 (UMLS CUI [2,1])
C0812409 (UMLS CUI [2,2])
C0034094 (UMLS CUI [3])
Mean pulmonary arterial pressure increased Exercise induced | Pulmonary Wedge Pressure Exercise induced | Pulmonary artery pressure Gradient Exercise induced | Heart Disease Left sided Absent | Lung disease Severe Absent | Hypertensive disease Absent
Item
2. exercise induced elevated mpap-values >30 mmhg, pawp <18 mmhg; tpg >15 mmhg, as defined in saggar et al. (2012) without left heart or severe lung disease or systemic arterial hypertension
boolean
C4087413 (UMLS CUI [1,1])
C0239313 (UMLS CUI [1,2])
C0034094 (UMLS CUI [2,1])
C0239313 (UMLS CUI [2,2])
C0428642 (UMLS CUI [3,1])
C0812409 (UMLS CUI [3,2])
C0239313 (UMLS CUI [3,3])
C0018799 (UMLS CUI [4,1])
C0443246 (UMLS CUI [4,2])
C0332197 (UMLS CUI [4,3])
C0024115 (UMLS CUI [5,1])
C0205082 (UMLS CUI [5,2])
C0332197 (UMLS CUI [5,3])
C0020538 (UMLS CUI [6,1])
C0332197 (UMLS CUI [6,2])
Adult | Age
Item
3. adult patients having completed his/her 18th birthday
boolean
C0001675 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
Systemic Sclerosis
Item
4. patients with definite diagnosis of systemic sclerosis using the scleroderma criteria of the american rheumatism association
boolean
C0036421 (UMLS CUI [1])
Systemic Sclerosis Disease length
Item
5. ssc-disease duration >3 years
boolean
C0036421 (UMLS CUI [1,1])
C0872146 (UMLS CUI [1,2])
Informed Consent
Item
6. able to understand and willing to sign the informed consent form
boolean
C0021430 (UMLS CUI [1])
Childbearing Potential Pregnancy test negative | Childbearing Potential Contraceptive methods
Item
7. negative pregnancy test at the start of the trial and appropriate contraception throughout the study for women with child-bearing potential.
boolean
C3831118 (UMLS CUI [1,1])
C0427780 (UMLS CUI [1,2])
C3831118 (UMLS CUI [2,1])
C0700589 (UMLS CUI [2,2])
Item Group
C0680251 (UMLS CUI)
Connective Tissue Diseases | Exception Systemic Sclerosis
Item
1. any connective tissue diseases (ctd) other than ssc
boolean
C0009782 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0036421 (UMLS CUI [2,2])
Pulmonary Hypertension Catheterization of right heart | Mean pulmonary arterial pressure At rest
Item
2. pulmonary hypertension (ph) confirmed by right heart catheter (rhc) before enrolment, i.e. mpap ≥25 mmhg at rest
boolean
C0020542 (UMLS CUI [1,1])
C0189896 (UMLS CUI [1,2])
C3854605 (UMLS CUI [2,1])
C0443144 (UMLS CUI [2,2])
Mean pulmonary arterial pressure Normal | Mean pulmonary arterial pressure At rest | Mean pulmonary arterial pressure Exercise induced | Pulmonary Wedge Pressure At rest | Pulmonary Wedge Pressure Exercise induced
Item
3. patients presenting normal mpap values, i.e. mpap<21 mmhg at rest, ≤30 mmhg during exercise, pawp >=15 mmhg at rest or <=18 mmhg during exercise
boolean
C3854605 (UMLS CUI [1,1])
C0205307 (UMLS CUI [1,2])
C3854605 (UMLS CUI [2,1])
C0443144 (UMLS CUI [2,2])
C3854605 (UMLS CUI [3,1])
C0239313 (UMLS CUI [3,2])
C0034094 (UMLS CUI [4,1])
C0443144 (UMLS CUI [4,2])
C0034094 (UMLS CUI [5,1])
C0239313 (UMLS CUI [5,2])
Therapy Pulmonary Hypertension | Endothelin receptor antagonist | bosentan | ambrisentan | Phosphodiesterase 5 inhibitor | sildenafil | tadalafil | vardenafil | Prostaglandins | Epoprostenol | Treprostinil | Iloprost | beraprost | Soluble Guanylate Cyclase Stimulator | riociguat
Item
4. ongoing or a history of >2 weeks of continued use of therapies that are considered definitive ph treatment: endothelin receptor antagonists (era; e.g. bosentan, ambrisentan), phosphodiesterase type 5 inhibitors (pde5; e.g. sildenafil, tadalafil, vardenafil), prostanoids (e.g. epoprostenol, treprostinil, iloprost, beraprost) and soluble guanylate cyclase stimulator (e.g. riociguat). intermittent use of pde5 inhibitors for male erectile dysfunction is permitted.
boolean
C0087111 (UMLS CUI [1,1])
C0020542 (UMLS CUI [1,2])
C1134681 (UMLS CUI [2])
C0252643 (UMLS CUI [3])
C1176329 (UMLS CUI [4])
C1318700 (UMLS CUI [5])
C0529793 (UMLS CUI [6])
C1176316 (UMLS CUI [7])
C0971579 (UMLS CUI [8])
C0033554 (UMLS CUI [9])
C0033567 (UMLS CUI [10])
C1145760 (UMLS CUI [11])
C0079594 (UMLS CUI [12])
C0053336 (UMLS CUI [13])
C3819023 (UMLS CUI [14])
C2717561 (UMLS CUI [15])
Exception Diuretics | Exception Adrenal Cortex Hormones | Therapeutic procedure unchanged
Item
5. except for diuretics and corticosteroids medical treatment should not be expected to change 4 weeks prior inclusion into the study and during the entire 12-week study period.
boolean
C1705847 (UMLS CUI [1,1])
C0012798 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C0001617 (UMLS CUI [2,2])
C0087111 (UMLS CUI [3,1])
C0442739 (UMLS CUI [3,2])
Intolerance to Ambrisentan | Intolerance to Ambrisentan Excipient
Item
6. known intolerance to ambrisentan or one of its excipients
boolean
C1744706 (UMLS CUI [1,1])
C1176329 (UMLS CUI [1,2])
C1744706 (UMLS CUI [2,1])
C1176329 (UMLS CUI [2,2])
C0015237 (UMLS CUI [2,3])
Anemia | Hemoglobin measurement
Item
7. clinically significant anemia (hemoglobin concentration of less than 75% of the lower limit of normal, lln)
boolean
C0002871 (UMLS CUI [1])
C0518015 (UMLS CUI [2])
FVC | FEV1
Item
8. forced vital capacity (fvc) <60%, forced expiratory volume in first second (fev1) <65%
boolean
C3714541 (UMLS CUI [1])
C0849974 (UMLS CUI [2])
Interstitial Lung Disease Severe | Idiopathic Pulmonary Fibrosis
Item
9. severe interstitial lung disease, idiopathic pulmonary fibrosis
boolean
C0206062 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C1800706 (UMLS CUI [2])
Renal Insufficiency | Glomerular Filtration Rate
Item
10. renal insufficiency (glomerular filtration rate [gfr] <60 ml/min/1.73m2 for at least 3 months)
boolean
C1565489 (UMLS CUI [1])
C0017654 (UMLS CUI [2])
Alanine aminotransferase increased | Aspartate aminotransferase increased
Item
11. baseline values of hepatic aminotransferases (alt and/or ast) >3 x upper limit of normal (uln)
boolean
C0151905 (UMLS CUI [1])
C0151904 (UMLS CUI [2])
Systolic Pressure
Item
12. systolic blood pressure <85 mmhg;
boolean
C0871470 (UMLS CUI [1])
Blood pressure determination | Therapy Inadequate | Blood pressure determination During Exercise
Item
13. evidence of inadequately treated blood pressure >160/90 mmhg and/or blood pressure during exercise >220/120 mmhg
boolean
C0005824 (UMLS CUI [1])
C0087111 (UMLS CUI [2,1])
C0205412 (UMLS CUI [2,2])
C0005824 (UMLS CUI [3,1])
C0347984 (UMLS CUI [3,2])
C0015259 (UMLS CUI [3,3])
Heart failure
Item
14. patients referred with clinically significant overt heart failure
boolean
C0018801 (UMLS CUI [1])
Body fluid retention
Item
15. clinically significant fluid retention
boolean
C0268000 (UMLS CUI [1])
Heart Disease Left sided | Estimated Left Ventricular Ejection Fraction Echocardiography | Cardiogenic pulmonary edema | Left atrium Size Increased
Item
16. previous evidence or diagnosis of clinically relevant left heart disease, i.e. at least one of the following: previous echocardiography with estimated left ventricular (lv) ejection fraction <50%, previous history of cardiogenic pulmonary edema, increased size of left atrium (>50 mm)
boolean
C0018799 (UMLS CUI [1,1])
C0443246 (UMLS CUI [1,2])
C4525751 (UMLS CUI [2,1])
C0013516 (UMLS CUI [2,2])
C0398350 (UMLS CUI [3])
C0225860 (UMLS CUI [4,1])
C0456389 (UMLS CUI [4,2])
C0205217 (UMLS CUI [4,3])
Diastolic dysfunction Associated with Heart failure
Item
17. known significant diastolic dysfunction associated with clinical heart failure
boolean
C0520863 (UMLS CUI [1,1])
C0332281 (UMLS CUI [1,2])
C0018801 (UMLS CUI [1,3])
Coronary Artery Disease | Heart valve disease
Item
18. known coronary disease or significant valvular heart disease
boolean
C1956346 (UMLS CUI [1])
C0018824 (UMLS CUI [2])
Congenital Heart Defects | Single Ventricle | Transposition | Eisenmenger Complex
Item
19. known congenital heart defects such as single ventricle, transposition, eisenmenger
boolean
C0018798 (UMLS CUI [1])
C3274516 (UMLS CUI [2])
C0040759 (UMLS CUI [3])
C0013743 (UMLS CUI [4])
Hypertrophic Cardiomyopathy | Left Ventricular Hypertrophy | Interventricular septum thickness increased | Posterior wall thickness increased
Item
20. known hypertrophic cardiomyopathy or left ventricular hypertrophy (interventricular septum thickness (ivs) or posterior wall thickness (pwd) >1.2 cm)
boolean
C0007194 (UMLS CUI [1])
C0149721 (UMLS CUI [2])
C3553443 (UMLS CUI [3])
C3553444 (UMLS CUI [4])
Study Subject Participation Status | Investigational New Drugs
Item
21. participation in any clinical drug trial within 4 weeks prior to screening of this study and/or who is scheduled to receive another investigational medicinal product (imp) during the course of this study
boolean
C2348568 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
Pregnancy | Breast Feeding
Item
22. pregnancy or lactation
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Voltar ao início da página 

Contacto

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial